StarZero All shows Try the podcast clipper →

Dave Ricks

Chair & CEO, Eli Lilly and Company · 2 appearances on the record.

computed by AI from the episodes · how this works → · full disclaimer →

executiveoperatorWikipedia ↗Instagram ↗

David A. Ricks has led Eli Lilly as CEO since 2017, overseeing its expansion into one of the world's most valuable pharmaceutical companies driven by blockbuster diabetes and obesity therapies like Mounjaro and Zepbound. Beyond Lilly, he serves on the board of directors of Adobe and the Purdue University Board of Trustees.

71statements → 57claims → 29claims resolved → 55%fully supported → 3.92/5average certainty → 2.03/5average debate potential → 4.2/5argument clarity · the sources → 1said about them ↓

16 supported 7 partly supported 6 contradicted 2 not yet assessed 26 not checkable as stated how the 57 claims stand · each chip opens the sources

12 predictions · 45 assertions · 3 opinions · 2 insights · 9 disclosures · every statement was checked. The predictions and assertions are the 57 claims: statements the public record can support or contradict. 29 are resolved, 2 are not yet assessed, and 26 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Dave argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported
Eli Lilly CEO: Tirzepatide surpassed Keytruda as best-selling drug ever
“And then terzepatide, which you asked how much money we're making, but in, actually in Q-two, we reported global sales, which surpassed Keytruda to becoming the best-selling drug in the world, actually the best-selling drug in the world of all time.”
Dave Ricks Sep 29, 2025 ▶ 3:11 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

Their most notable contradicted claim

Assertion Contradicted
Ricks: Eli Lilly's GLP-1 drugs are undefeated in chronic disease trials
“So far in our studies, this category of medicine's undefeated. We've never had an unsuccessful study in measuring an outcome in a chronic disease.”
Dave Ricks Oct 8, 2024 ▶ 25:00 Dave Ricks, CEO of Eli Lilly | The All-In Interview

Expressed certainty vs assessment result

none yet certainty 1
none yet certainty 2
75% certainty 3
59% certainty 4
78% certainty 5

weighted support: a fully supported claim counts one, a partly supported claim counts half. Each filled bar is clickable and opens exactly those claims; "none yet" means nothing said at that certainty level has resolved yet

Argument clarity: do they answer the question? how? →

4.2 / 5 directness 4.5 · coherence 4.6 · precision 4.3 · compression 3.8

redirected or did not address 1 of 12 assessed questions (8%). Watch them ▸

This is a score against a rubric. It is not a rank. Every host question → answer exchange is scored with names hidden on directness, coherence, precision and compression, 1–5 each, on meaning alone: disfluencies are ignored, and only raw unedited episodes count. This is the score that measures thought. Every scored exchange, scores shown → · The rubric and its checks →

How they sound: speaking style how? →

265 words/min while actually speaking · 17 um and uh per 1k words

Measured by listening to the audio itself: 12,023 words across 2 episodes of raw-level tape, transcribed verbatim with every um and uh kept, each one attributed only where the alignment onto our timed stream is unambiguous. These are measurements of speaking style. We do not rank them: across this corpus, fluency and argument quality are nearly uncorrelated (ρ≈0.2), and smooth talking does not signal clear thinking. How it's measured →

Everything Dave Ricks said on All-In that made the record, most notable first. Filter by type, assessment or year in the ledger →

Assertion Not checkable as stated
Dave Ricks: Brain diseases account for 40% of global human suffering
“I think if you look at human suffering globally, 40% is brain diseases”
Dave Ricks Sep 29, 2025 ▶ 29:33 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Supported
Eli Lilly and Genentech partnered to create the first-ever biotechnology product
“We had partnered with Genentech to do another first, which is create the first biotechnology product on planet earth, which was human insulin made in a bacterial cell.”
Dave Ricks Oct 8, 2024 ▶ 11:25 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Not checkable as stated
Science does not yet fully understand GLP-1's secondary metabolic effects
“What we don't even fully understand yet though, David, which is interesting is, is that there are primary effects of GLP-I. Certainly we can reproduce like in a test tube or a cell system, but then there's a whole myriad of other probably secondary effects bec…”
Dave Ricks Oct 8, 2024 ▶ 22:19 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Contradicted
Ricks: Eli Lilly has 105 active tirzepatide clinical trials
“Currently, Lily has a 105 studies going with trisapatide in these other diseases.”
Dave Ricks Oct 8, 2024 ▶ 25:17 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Prediction Not checkable as stated
Dave Ricks: Employers not covering weight-loss meds will look crazy in five years
“I think in five years we'll look back and we'll say that was crazy. Once the evidence base is built up and there's more adoption and less stigma, but right now that's the current state.”
Dave Ricks Oct 8, 2024 ▶ 31:18 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Supported
Eli Lilly oral GLP-1 shows efficacy matching high-dose semaglutide in trials
“In our hands, it, it's about as good as high dose semaglutide, and we, we're doing phase three right now. So that will start to read out next year.”
Dave Ricks Oct 8, 2024 ▶ 36:44 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Not checkable as stated
Ricks: Eli Lilly has regulatory approvals in 40+ unlaunched countries
“We have approvals in more than 40 countries we haven't even launched in.”
Dave Ricks Oct 8, 2024 ▶ 37:13 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Disclosure
Eli Lilly CEO expects 2024 R&D spending to exceed $11B
“This year we'll spend over eleven billion dollars on R&D, which is a meaningful it's like a nation state scale.”
Dave Ricks Oct 8, 2024 ▶ 41:51 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Not checkable as stated
Ricks: Brain and neuroscience diseases cause 40% of global suffering
“About 40% of global suffering is some form of a brain or neuroscience disease.”
Dave Ricks Oct 8, 2024 ▶ 49:39 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Supported
Dave Ricks: Eli Lilly gene therapy restored hearing in congenitally deaf children
“We've treated patients that have gone from like six, eight years of life, no hearing at all to now hearing.”
Dave Ricks Oct 8, 2024 ▶ 52:19 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Supported
Dave Ricks: Eli Lilly has Phase 3 siRNA drug targeting Lp(a)
“We have a project in phase three right now that knocks down the production of something called LpA, which is a lipoprotein particle that's probably thought to be about 25% of the remnant reasons why we still have cardiovascular disease and there's no medicine …”
Dave Ricks Oct 8, 2024 ▶ 52:57 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Contradicted
Ricks: Eli Lilly acquired 24 companies for $3B last year
“We buy companies last year, about two dozen, which was the most of any pharma company, but actually with some of the least capital deployed. So we're making I think we spent three billion dollars on 24 companies.”
Dave Ricks Oct 8, 2024 ▶ 55:19 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Not checkable as stated
Eli Lilly reduced its drug development timeline from 11 to 6.1 years
“We've moved the drug development timeline, which the industry is about nine years, from first human dose to FDA approval. And when I started, ours was about 11. And now we're 6.1.”
Dave Ricks Oct 8, 2024 ▶ 58:41 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Not checkable as stated
Ricks: Eli Lilly cut FDA submission prep time to under two weeks
“We have a submission document to get in and it used to be our standard was a 120 days from when you had the data to when you send it to the FDA. We're now doing that routinely inside of two weeks.”
Dave Ricks Oct 8, 2024 ▶ 59:25 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Contradicted
Dave Ricks: Tech VCs invested $5B in AI drug discovery startups last year
“I think last year, five billion with a B went into new venture backed You know, that's what they like to call themselves. And that money is coming not so much from the traditional bio VC world, but from the tech world. Got a lot more to splash around, right?”
Dave Ricks Oct 8, 2024 ▶ 1:01:20 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Disclosure
Eli Lilly has over 100 clinical studies underway for tirzepatide
“We currently have over a hundred clinical studies with the medicine going on for all kinds of other uses as well, not just slowing you down.”
Dave Ricks Sep 29, 2025 ▶ 5:02 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Prediction Held up
Eli Lilly's US expansion creates over 25,000 construction and manufacturing jobs
“So yeah, this is creating 20,000 construction jobs in this period, and ultimately five or 6000 manufacturing jobs.”
Dave Ricks Sep 29, 2025 ▶ 12:03 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Disclosure
Eli Lilly completes an external acquisition or partnership roughly every two weeks
“We're doing a deal about every two weeks.”
Dave Ricks Sep 29, 2025 ▶ 12:40 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Disclosure
Dave Ricks personally uses AI models to audit information on his drugs
“I do do it myself. I also do it just to see what the different models are producing about our drugs.”
Dave Ricks Sep 29, 2025 ▶ 24:26 Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Assertion Not checkable as stated
Dave Ricks: 230 diseases are linked to obesity and caloric imbalance
“230 diseases have been connected and you have these pr, these ones that are more like directly because of the caloric imbalance and fat accumulation.”
Dave Ricks Oct 8, 2024 ▶ 8:17 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Supported
Ricks: Native GLP-1 has a half-life of minutes in medicine
“When you give it in its native form as a medicine, it has a half-life of like minutes.”
Dave Ricks Oct 8, 2024 ▶ 16:27 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Supported
Ricks: GLP-1 glucose regulation triggers at lower doses than weight loss
“The glucose effect occurs at a lower dose than the weight loss effect.”
Dave Ricks Oct 8, 2024 ▶ 18:10 Dave Ricks, CEO of Eli Lilly | The All-In Interview
Assertion Supported
Ricks: Novo Nordisk's higher semaglutide dosing enabled obesity treatment
“So it was really Novo's insight that we could push up the dose of semaglutide that allowed the obesity Kind of threshold to be pushed.”
Dave Ricks Oct 8, 2024 ▶ 18:34 Dave Ricks, CEO of Eli Lilly | The All-In Interview

The other half of the tape: Dave Ricks's own voice is left out of every number here. Other people bring the name up 1 time in 1 episode on All-In. every mention, with the transcript →

Who brings them up most Chamath Palihapitiya 1

Every mention by year

tap a year for its mentions
0011112024episodesmentions
0112024episodes it came up in
000.50.5112024episodesmentions per episode
2024 1 mention in 1 episode

Appearances (2)

EpisodeDateSpeaking time
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Sep 29, 2025 18m
Dave Ricks, CEO of Eli Lilly | The All-In Interview Oct 8, 2024 37m
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 460 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more